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Abstract: The physiological process by which Ca2+ is released from the 
sarcoplasmic reticulum is called excitation-contraction coupling; it is 
initiated by an action potential which travels deep into the muscle fiber 
where it is sensed by the dihydropyridine receptor, a voltage sensing L-
type Ca2+channel localized on the transverse tubules. Voltage-induced 
conformational changes in the dihydropyridine receptor activate the 
ryanodine receptor Ca2+ release channel of the sarcoplasmic reticulum. 
The released Ca2+ binds to troponin C, enabling contractile thick-thin 
filament interactions. The Ca2+ is subsequently transported back into the 
sarcoplasmic reticulum by specialized Ca2+ pumps, preparing the muscle 
for a new cycle of contraction. Although other proteins are involved in 
excitation-contraction coupling, the mechanism described above emphasizes 
the unique role played by the two Ca2+ channels (the dihydropyridine 
receptor and the ryanodine receptor), the SERCA Ca2+ pumps and the 
exquisite spatial organization of the membrane compartments endowed with 
the proteins responsible for this mechanism to function rapidly and 
efficiently. Research over the past two decades has uncovered the fine 
details of excitation-contraction coupling under normal conditions while 
advances in genomics have helped to identify mutations in novel genes in 
patients with neuromuscular disorders. While it is now clear that many 
patients with congenital muscle diseases carry mutations in genes 
encoding proteins directly involved in Ca2+ homeostasis, it has become 
apparent that mutations are also present in genes encoding for proteins 
not thought to be directly involved in Ca2+ regulation. Ongoing research 
in the field now focuses on understanding the functional effect of 
individual mutations, as well as understanding the role of proteins not 
specifically located in the sarcoplasmic reticulum which nevertheless are 
involved in Ca2+ regulation or excitation-contraction coupling. The 
principal challenge for the future is the identification of drug targets 
that can be pharmacologically manipulated by small molecules, with the 
ultimate aim to improve muscle function and quality of life of patients 
with congenital muscle disorders. The aim of this review is to give an 
overview of the most recent findings concerning Ca2+ dysregulation and 
its impact on muscle function in patients with congenital muscle 
disorders due to mutations in proteins involved in excitation-contraction 
coupling and more broadly on Ca2+ homeostasis. 
 
 
 
 
HIGHLIGHTS  
 Dysregulation of calcium homeostasis in skeletal muscle leads to different 
forms of congenital neuromuscular disorders. 
 Mutations in different genes can affect calcium regulation and excitation-
contraction coupling either directly or indirectly. 
 Secondary pathogenic downstream mechanisms activated as a consequence of 
a mutation may converge into similar pathogenic pathways. 
 Such pathogenic pathways may be amenable to pharmacological intervention. 
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ABSTRACT 
The physiological process by which Ca
2+
 is released from the sarcoplasmic 
reticulum is called excitation-contraction coupling; it is initiated by an action potential 
which travels deep into the muscle fiber where it is sensed by the dihydropyridine 
receptor, a voltage sensing L-type Ca
2+
channel localized on the transverse tubules. 
Voltage-induced conformational changes in the dihydropyridine receptor activate the 
ryanodine receptor Ca
2+ 
release channel of the sarcoplasmic reticulum. The released 
Ca
2+ 
binds to troponin C, enabling contractile thick-thin filament interactions. The 
Ca
2+ 
is subsequently transported back into the sarcoplasmic reticulum by specialized 
Ca
2+ 
pumps, preparing the muscle for a new cycle of contraction. Although other 
proteins are involved in excitation-contraction coupling, the mechanism described 
above emphasizes the unique role played by the two Ca
2+ 
channels (the 
dihydropyridine receptor and the ryanodine receptor), the SERCA Ca
2+ 
pumps and the 
exquisite spatial organization of the membrane compartments endowed with the 
proteins responsible for this mechanism to function rapidly and efficiently. Research 
over the past two decades has uncovered the fine details of excitation-contraction 
coupling under normal conditions while advances in genomics have helped to identify 
mutations in novel genes in patients with neuromuscular disorders. While it is now 
clear that many patients with congenital muscle diseases carry mutations in genes 
encoding proteins directly involved in Ca
2+ 
homeostasis, it has become apparent that 
mutations are also present in genes encoding for proteins not thought to be directly 
involved in Ca
2+ 
regulation. Ongoing research in the field now focuses on 
understanding the functional effect of individual mutations, as well as understanding 
the role of proteins not specifically located in the sarcoplasmic reticulum which 
nevertheless are involved in Ca
2+ 
regulation or excitation-contraction coupling. The 
principal challenge for the future is the identification of drug targets that can be 
pharmacologically manipulated by small molecules, with the ultimate aim to improve 
muscle function and quality of life of patients with congenital muscle disorders. The 
aim of this review is to give an overview of the most recent findings concerning Ca
2+ 
dysregulation and its impact on muscle function in patients with congenital muscle 
disorders due to mutations in proteins involved in excitation-contraction coupling and 
more broadly on Ca
2+ 
homeostasis. 
 3 
KEY WORDS: Ca
2+ 
homeostasis, sarcoplasmic reticulum, excitation-contraction 
coupling, congenital myopathies, ryanodine receptor, dihydropyridine receptor, 
SERCA, mutations. 
 
1 INTRODUCTION 
1.1 The sarcoplasmic reticulum and Ca
2+
 regulation. 
The sarcoplasmic reticulum (SR) is a specialized intracellular membrane 
compartment present in striated muscles almost completely dedicated to Ca
2+ 
regulation. The SR can be subdivided into different functional domains that are each 
enriched in specific Ca
2+
 handling and structural proteins. The transverse tubules (T-
tubules) are invaginations of the plasma membrane and contain the voltage sensing 
dihydropyridine receptor (DHPR). The portion of the SR terminal cisternae 
membrane facing the T- tubules is called junctional face membrane and contains the 
ryanodine receptor Ca
2+ 
release channel (RyR1), regulatory and structural proteins 
such as JP-45, triadin and junctin as well as a number of other proteins that are part of 
the RyR1 Ca
2+ 
release channel macromolecular structure [1-4]. Figure 1 illustrates the 
main protein components of the excitation-contraction coupling machinery in 
mammalian skeletal muscle. 
The sarcoplasmic/endoplasmic reticulum Ca
2+
 ATPase (SERCA) is the main 
protein of the longitudinal sarcoplasmic reticulum, accounting for >70% of its total 
protein content. SERCAs belong to class P-type ATPases and are responsible for 
replenishing the SR with Ca
2+
 after its release following excitation- contraction 
coupling [2,4,5]. In striated muscle, SERCA activity can be modulated by two small 
regulatory proteins, sarcolipin and phospholamaban [5,6]. Sarcolipin decreases the 
affinity of SERCA1a and SERCA2a for Ca
2+ 
thereby inhibiting its
 
re-uptake in the SR 
and diminishing the SR Ca
2+
 stores. In humans it is expressed in both fast and slow 
twitch muscles as well as in cardiac muscle [7,8]. Phospholamban, which is expressed 
in cardiac and slow twitch muscles, acts as an inhibitor of SERCA2a when present in 
the unphosphorylated form, but upon phosphorylation by PKA its inhibitory effects 
are abolished [9,10]. Interestingly sarcolipin and phospholamban share ~30% identity 
and have been proposed to bind to the same domain on SERCA2a [5,6,11].  
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Myoregulin is a recently identified skeletal muscle-specific micropeptide sharing 
structural similarities with sarcolipin and phospholamban. Myoregulin interacts with 
SERCA1 and by so doing decreases the pump’s activity [12]. Its deletion in mice 
enhances Ca
2+
 handling and improves exercise performance, suggesting that 
myoregulin plays an important physiological role in regulating skeletal muscle Ca
2+ 
homeostasis. 
 
1.2 Excitation-contraction coupling 
Excitation-contraction coupling (ECC) is the process whereby an electrical 
signal generated by an action potential is converted into a chemical gradient, that is an 
increase in the myoplasmic [Ca
2+
], leading to muscle contraction [13,14]. In order for 
ECC to occur efficiently it relies on a highly sophisticated subcellular architecture 
where voltage sensing L-type Ca
2+
 channels (DHPRs) lie opposite RyR1 in a highly 
organized conformation resembling a checkerboard, with every other RyR1 facing a 
DHPR [15, 16]. The DHPR is a macromolecular complex made up of at least five 
subunits present in a 1:1:1:1:1 ratio, including Cav1.1 (or 1.1), the channel pore that 
interacts through its II-III loop with the RyR1, as well as the 2, ∂, ß and  subunits 
[17]. Several diseases have been linked to mutations in CACNA1S the gene encoding 
Cav1.1, including some forms of hypokalemic periodic paralysis and malignant 
hyperthermia [18-20]. 
The RyR1 is a huge macromolecular complex of >2.5 MDa made up of 4 
homotetramers of ≈565 kDa each that assemble into a functional Ca2+ release channel. 
The first 4000 amino acids make up the large cytoplasmic domain that contains 
binding sites for various modulators while the last 1000 amino acids constitute the 
carboxy terminal pore-forming domain [21-22]. Dominant and recessive mutations in 
RYR1, the gene encoding the RyR1, are associated with a range of early-onset 
neuromuscular disorders including the core myopathies central core disease (CCD) 
and multi-minicore disease (MmD), congenital fiber type disproportion, (CFTD) 
centronuclear myopathy (CNM), exertional rhabdomyolysis/myalgia as well as the 
pharmacogenetic disorder malignant hyperthermia (MH) [23-26].  
Aside the RyR1, the junctional sarcoplasmic reticulum is enriched in several 
other proteins including the structural proteins triadin and junctin, as well as minor 
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constituents such as JP-45, junctate and humbug, mitsugumin-29, SRP-27/TRIC-A 
and junctophilin-1 [4, 27-29]. These minor constituents play a role in the fine 
regulation of Ca
2+
 release from the SR or are involved in maintaining the structural 
integrity of the Ca
2+
 release machinery. The other major constituent of the junctional 
face membrane is the high capacity low affinity Ca
2+
 binding protein calsequestrin. In 
the presence of millimolar Ca
2+
 (that is at a concentrations similar to those present at 
rest in the lumen of the SR) calsequestrin polymerizes and forms a mesh- like 
structure in an area adjacent to the RyR1 [29-31]. The luminal domain of junctin 
interacts directly with calsequestrin and together with triadin forms a complex that is 
thought to have a dual role: (i) maintaining calsequestin adjacent to the RyR1 and (ii) 
sensing the amount of Ca
2+
 in the lumen of the SR [31, 32]. Two isoforms of 
calsequestrin have been identified: calsequestrin1 that is predominantly expressed in 
fast twitch skeletal muscles and calsequestrin 2 that is expressed in cardiac and slow 
twitch muscle. Mutations in CSQ2 (the gene encoding calsequestrin 2) have been 
linked to catecholaminergic polymorphic ventricular tachycardia (CPVT), sudden 
cardiac arrest and heart failure [33,34] and will not be discussed in this review, 
whereas mutations in CSQ1 (the gene encoding calsequestrin 1) have been implicated 
in a case of malignant hyperthermia and vacuolar aggregate myopathy [35,36].  
 
2.1 Pathological consequences of mutations in genes encoding 
proteins directly involved in ECC  
2.1.1 Disorders associated with RYR1 mutations 
The first mutation identified in RYR1, the gene encoding the skeletal muscle 
RyR1 was linked to Malignant Hyperthermia Susceptibility (MHS) a 
pharmacogenetic disorder triggered by halogenated anesthetics and by the muscle 
relaxant succinylcholine [37]. Since this initial discovery in the early 90s, more than 
200 mutations have been identified in patients with a variety of induced myopathies 
including MHS, exertional rhabdomyolysis/myalgia and a range of congenital 
myopathies including CCD, as well as subgroups of MmD, CNM and CFTD [23-26]. 
Because of the sheer size of the RYR1 gene which spans 106 exons and >15 kb DNA, 
initial mutation searches were confined to hotspot domains originally implicated in 
 6 
autosomal dominant MHS and CCD. However, thanks to technical advances in DNA 
sequencing and genome analysis, a more systematic examination of the RYR1 gene 
became possible and revealed that mutations, especially recessive ones, can affect the 
entire coding region of the RYR1 gene. The calculated frequency of RYR1 mutations 
is approximately 1:3000 making it one of the most commonly mutated genes 
associated with neuromuscular disorders [38-40]. A number of reviews concerning 
the frequency, disease associations and functional impact of RYR1 mutations have 
been published in recent years and the reader is referred to these for a more in depth 
description (for example see [12-24,41-45]. The disease phenotype resulting from 
RYR1 mutations largely depends on their location within the RYR1 coding sequence 
and whether the mutations are dominant or recessive. Dominant mutations are more 
commonly associated with the MHS or exertional rhabdomyolysis and CCD 
phenotypes, while most cases of MmD, CNM and CFTD are associated with 
recessive mutations. From a general point of view, dominant RYR1 mutations affect 
the biophysical properties of the Ca
2+
 channel while the mode of action of recessive 
mutations has been more difficult to decipher. For gain-of-function dominant MHS-
linked mutations that render the Ca
2+
 channel hypersensitive and thus more prone to 
be in the open conformation, the amino acid substitutions induce local protein 
misfolding or affect the intersubunit domain-domain interfaces; the resulting 
tetrameric channels are deregulated leading to a leak of Ca
2+
 into the cytoplasm or to 
an excessive amount of Ca
2+
 release from the SR [22, 24, 46-49]. This results in a 
number of direct effects in the muscle fibers including a higher resting [Ca
2+
], a shift 
in the sensitivity to activating signals (depolarization, pharmacological stimulation), 
greater depolarization induced Ca
2+
 influx, that can all lead to a hypermetabolic state 
which is the underlying feature of MHS.  
Dominant mutations associated with CCD induce weak muscles either because 
they render the RyR1 channels less efficient at transporting Ca
2+
, or because they lead 
to store depletion [50,51]. Though the functional impact of the mutation is important 
in order to develop an appropriate pharmacological approach, both types of mutations 
lead to changes in the biophysical properties of the RyR1 and cause weak muscles 
because Ca
2+ 
is not available to bind to the contractile proteins and initiate contraction. 
Two important aspects concerning the effects of dominant RYR1 mutations still 
require clarification. One relates to the protomer composition of the Ca
2+
 channel in 
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individuals carrying dominant RYR1 mutations, while the other is related to secondary 
downstream effects. It is very difficult, if not impossible, to establish the exact 
protomer composition of the RyR1 protein complex in individuals carrying dominant 
RYR1 mutations. A variation in the proportion of protomers encoded by wild type and 
mutated alleles within the tetrameric RyR1 Ca
2+
 channel complex will undoubtedly 
affect the biophysical properties of the Ca
2+
 channel [52], possibly contributing to the 
phenotypic variation seen in patients carrying the same RYR1 mutations.  
The primary defects in Ca
2+ 
regulation
 
caused by dominant RYR1 mutations 
will also lead to secondary downstream effects in the muscle fibers such as increased 
release of inflammatory cytokines, mitochondrial abnormalities, modifications due to 
the excessive generation of reactive oxygen and nitrogen species, and changes in 
transcriptional regulation including those that are dependent on activation of the 
Ca
2+–sensitive NFAT transcription factors [50,53,54]. An example of such an effect is 
illustrated in figure 2, showing that in myotubes from patients with CCD carrying 
dominant RYR1 mutations, the nuclear to cytoplasmic ratio of NFATc1 is higher than 
in myotubes from control individuals, under resting non-stimulated conditions. 
Furthermore, the nuclear to cytoplasmic ratio of NFATc1 increases dramatically after 
KCl-induced depolarization (Fig. 2 A and B) [53]. Moreover, even in the absence of 
inflammatory conditions (as suggested by the lack of upregulation of the C-reactive 
protein, a marker of inflammation) the serum content of pro-inflammatory cytokines 
such as IL-6, is chronically elevated in individuals carrying dominant RYR1 mutations 
(panel C), but the functional consequences of such changes are largely unknown. 
From figure 2 it is also apparent that the control and MmD (as a result of 
recessive RYR1 mutations) groups are more similar in their serum IL-6 levels and this 
is probably linked to the functional effect of the mutations. Indeed, in myotubes from 
patients with recessive RYR1 mutations no dysregulation of Ca
2+ 
homeostasis was 
detected [55]. This result is puzzling since muscle biopsies from the same patients 
show significant depletion of RyR1 protein, which should lead to a pronounced 
reduction of the amount of Ca
2+ 
released following RyR1 activation [55-57]. In a 
recent study we addressed the pathophysiology of recessive RYR1 mutations and in 
particular the epigenetic mechanism(s) responsible for bringing about such a drastic 
decrease of RyR1 protein in the muscles of patients [55]. Interestingly, most patients 
harboring recessive RYR1 mutations exhibit a 6-16 fold increase in class II histone de-
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acetylase protein content (HDAC-4 and HDAC-5) and hypermethylation of (at least) 
a CpG island within the RYR1 gene. Class II HDACs can bind to and sequester the 
muscle transcription factor mef-2 [58], thus one would expect that an increase in 
HDAC-4/5 expression would prevent the transcription of mef-2 dependent genes, 
which is indeed what was found. Muscle biopsies of patients with recessive RYR1 
mutations not only showed reduced RyR1 protein levels, but also reduced myomesin 
content (a mef-2 dependent protein) and a significant down-regulation of muscle 
specific micro RNAs including miR-22, miR-124, miR-1 and miR-133 [55]. Our 
hypothesis is illustrated in figure 3 where it is shown that the down-regulation of 
RyR1 is a consequence of the activation of a pathological epigenetic loop in skeletal 
muscle. These results are novel and will require further investigations in animal 
models, but if confirmed they will open new pathways for the treatment of muscle 
disorders which would then not target directly the primary genetic defect, but the 
downstream effects (in this case methylation and HDAC activation) which are 
hyperactivated in patients with neuromuscular diseases due to recessive RYR1 
mutations and most likely also in patients with neuromuscular disorders due to 
mutations in other genes, increasing the significance of these findings.  
2.1.2 Disorders associated with CACNA1S mutations  
In skeletal muscle, the RyR1 and DHPR constitute a signaling complex 
whereby orthograde (or forward) coupling between the two complexes activates Ca
2+
 
release via the opening of RyR1 channels, while retrograde signaling from the RyR1 
back to the DHPR regulates the magnitude of the L-type inward Ca
2+
 current carried 
by the DHPR [13,14,21]. In primary myotubes depolarizing stimuli that do not 
substantially deplete Ca
2+ 
stores can rapidly activate Ca
2+
 entry through a complex 
made up of RyR1, DHPR and a Ca
2+
 entry channel via a mechanism called excitation 
coupled Ca
2+
 entry (ECCE) [59,60]. Experimental evidence supporting a pathogenic 
role of enhanced ECCE in MHS was provided by Cherednichenko et al. [61] in mice 
knocked in for the RYR1 p.R163C mutation. Studies on skeletal muscles from these 
mice demonstrated: (i) that they exhibited enhanced depolarization induced Ca
2+
 entry, 
(ii) that this influx of Ca
2+
 did not occur via store activated Ca
2+
 entry, but via ECCE 
and (iii) that it is sensitive to dantrolene the drug that is clinically used to revert MH 
reactions. Increased ECCE in myotubes from patients with dominant RYR1 mutations 
was also observed by Treves et al. [53] providing further experimental evidence that 
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pathological dysregulation of Ca
2+
 homeostasis is not only caused by effects on the 
RyR1, but also by alteration of Ca
2+
 influx of skeletal muscles. 
Although more than 50% of MHS cases are caused by RYR1 mutations that 
render the Ca
2+ 
channel hypersensitive, rare mutations either at the heterozygous or 
homozygous state have been identified in CACNA1S, the gene encoding the 1.1 
subunit of the DHPR [18-20,62]. The presence of the CACNA1S p.R174W mutation 
affects Ca
2+
 homeostasis by altering the regulation of the RyR1 by Cav1.1. The RyR1 
becomes leaky, resulting in an increased resting [Ca
2+
] and partial depletion of SR 
Ca
2+
 stores. Though no studies on Ca
2+
 influx or altered ECCE were performed on 
cells carrying this mutation, the increased resting [Ca
2+
] was insensitive to nifedipine 
suggesting that at least in this case, the pathological effect is due to the lack of RyR1 
inhibition by the DHPR at rest [63]. Similar conclusions were reached when studying 
the effects of the CACNA1S p.R1086H mutation in myotubes, although in the latter 
case the CACNA1S mutation results in the enhanced sensitivity of the RyR1 to 
activation by both endogenous and exogenous activators [64].  
 
2.1.3 STAC3 mutations and Native American myopathy 
The first indication that patients with Native American myopathy, a peculiar 
myopathy affecting the Native American Lumbee population, may have a defect in 
Ca
2+
 regulation was the finding that they have an increased susceptibility to 
Malignant Hyperthermia, in the absence of RYR1 mutations [65]. Many individuals 
with North American myopathy however, present a phenotype that is reminiscent of 
that of patients with RYR1 mutations, including progressive scoliosis, short stature 
and dysmorphic features resembling RYR1-related King Denborough syndrome (KDS 
[65, 66]. The first report regarding the underlying molecular mechanism of this 
disorder was the identification of the recessive STAC3 p.W284S mutation. This 
mutation was not only identified in patients with North American myopathy, but also 
in a naturally occurring zebrafish mutant showing defective swimming [67 and 
Muntoni et al, personal observation]. The ECC mechanism of these mutant fish was 
severely compromised as shown by the reduced Ca
2+
 transients in both fast and slow 
twitch muscles, but there were no changes in the architecture of the T-tubules or SR 
membranes, even though Stac3 forms a complex with the DHPR and RyR1.  
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STAC3 KO mice die soon after birth because of breathing impairment 
[68,69]; muscles from newborn mice exhibit a decrease in muscle mass, centrally 
located nuclei and importantly, no contraction and no Ca
2+
 release in response to 
depolarization. Skeletal muscles from STAC3 KO mice respond normally to the 
RyR1 pharmacological agonist 4-chloro-m-cresol, indicating that RyR1 function is 
normal [69]. These results indicate that the absence of Stac3 affects the voltage 
sensing DHPR but not the SR Ca
2+ 
channels, a result that was confirmed recently 
when it was shown that in skeletal muscle Stac3 is required for surface expression of 
Cav1.1 [70]. Clearly much remains to be investigated on how mutation in STAC3 
cause such a strong muscle phenotype and are linked to MHS.  
2.1.4 CASQ1 mutations and vacuolar aggregate myopathy 
Calsequestrin 1, the Ca
2+
 storing protein of skeletal muscle, is a low affinity 
high capacity Ca
2+
 binding protein present in the lumen of the SR. At luminal resting 
[Ca
2+
] calsequestrin forms polymers that are thought to make available large amounts 
of Ca
2+
 in close proximity to the RyR1. In the past year, two reports have appeared 
linking mutations in CASQ1 to vacuolar aggregate myopathy [35,71]. Patients 
carrying the heterozygous CASQ1 p.D244G mutation, affecting a residue that lies 
within the Ca
2+
 binding domain of calsequestrin 1, have a mild myopathy, suffer from 
muscle cramps, elevated CK levels, reduced muscle strength and fatigue. From a 
functional point of view, muscle fibers isolated from these patients (i) show decrease 
Ca
2+
 release following caffeine administration, (ii) display increased glycogen content 
and mis-oriented junctions, (iii) an increase by approximately 25% of calsequestrin 1 
content and (iv) a lower content of polymerized calsequestin [35,71]. Interestingly a 
report on the physicochemical properties of wild type and p.D244G mutated CASQ1 
showed that the mutation reduces the Ca
2+
 binding properties of calsequestrin 1 and 
causes it to form large aggregates in vitro [36].  It should be pointed out that all the 
patients identified so far were heterozygous for the causative CASQ1 mutation, while 
the functional studies were performed on homozygous mutated calsequestrin 1 
molecules. Thus it is likely that the mild phenotype of the patients may be due to the 
presence of wild type calsequestrin 1 molecules within the SR. Of interest, CASQ1 
KO mice exhibit heat intolerance leading to an MH-like phenotype, enhanced 
oxidative stress, mitochondrial damage and reduced levels of releasable Ca
2+
 [72,73]. 
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2.2 Congenital myopathies due to mutations in genes involved in Ca
2+
 
entry pathways and SR Ca
2+ 
uptake 
Skeletal muscle fibers express two distinct calcium entry mechanisms: (i) 
calcium entry activated by depletion of sarcoplasmic reticulum stores (Store Operated 
Calcium Entry, SOCE) [74-76] and (ii) Ca
2+
 entry via the voltage sensing DHPR 1.1 
subunit, also referred to as ECCE (see section 2.1.2 where disorders associated with 
CACNA1S mutations are described), which is triggered either by a train of action 
potentials or by prolonged depolarization [59,60,77]. 
2.2.1 Disorders of SOCE: tubular aggregate myopathy 
Dominant mutations in STIM1 and ORAI1 have been linked to muscle 
disorders classified as tubular aggregate myopathy. This group of myopathies 
comprise rare, slowly progressive disorders causing either weakness or stiffness of 
proximal muscles [78-82]. STIM1 and ORAI1 encode respectively stromal interacting 
protein 1 (Stim1) and Orai1 or Calcium Release Activated Ca
2+ 
Influx channel 
(CRAC), proteins that are ubiquitously expressed and play a major role in SOCE [83]. 
Remarkably, recessive loss-of-function mutations are associated with immune 
deficiency syndromes characterized by T-cell dysfunction [78,79].  Two different 
models have been proposed for the activation of SOCE, one is slow and occurs in 
most cells, while the other is rapid and occurs in skeletal muscle. In resting conditions, 
Stim1 binds Ca
2+
 and is distributed throughout the ER membrane, while Orai1 
channels are localized on the plasma membrane. Upon Ca
2+
 store depletion, Ca
2+
 
unbinds from Stim1 causing its re-localization to ER punctae adjacent to the plasma 
membrane. The latter event leads to the recruitment of Orai1 into the plasma 
membrane domain associated with ER punctae, and the conformational coupling of 
Stim1 to Orai1 results in the activation of SOCE. This process is slow, requiring tens 
of seconds to develop in non-muscle cells [83]. In patients with loss of function 
mutations in STIM1 and ORAI1 Ca
2+ 
influx in T cells is severely affected, resulting in 
impaired T-cell proliferation [78,79,84].  
Evidence that depletion of Ca
2+
 from the SR activates Ca
2+
 entry in skeletal 
muscles was unambiguously provided by Kurebayashi and Ogawa [74], who 
demonstrated that store depletion activated Ca
2+
 influx is sensitive to Ni
2+
 and 
 12 
resistant to nifedipine and that it is inhibited by membrane depolarization. These 
results suggest that the properties of this Ca
2+ 
influx pathway
 
are similar to CRAC 
channels and some TRP channels.
 
Using an elegant experimental approach 
Launikonis and Rios [85] provided experimental results supporting a role for SOCE 
in mammalian skeletal muscles. They showed that in isolated rat EDL, SOCE: (i) is 
activated by release of Ca
2+ 
from the SR but does not require complete depletion of 
Ca
2+ 
stores; (ii) its rate of activation is independent of the magnitude of the Ca
2+
 
transient; and (iii) occurs rapidly, requiring less than 1 second following Ca
2+
 release 
from the SR. This rapid SOCE activation in skeletal muscle is most likely due to the 
lack of Stim1 re-localization from the SR/ER membrane to the plasma membrane 
because of its pre-clustering at the junctional SR membrane prior to store depletion 
[85]. Thus Stim1 and Orai1 are likely (but probably not the only) candidates 
mediating SOCE in mature mammalian skeletal muscles. A link between mutations in 
proteins mediating SOCE and myopathies was unequivocally provided (i) by the 
creation of a STIM1 KO mouse model, (ii) the identification of dominant mutations in 
STIM1 and ORAI1 in patients with tubular aggregate myopathy and (iii) the finding 
that the absence of Orai1 not only leads to immunological defects but also to a subtle 
myopathic phenotype. Homozygous STIM1 KO is almost always neonatally lethal 
with the few surviving pups being substantially smaller, with reduced body weight 
and having weak fatigable muscles [86]. Histological examination of muscles from 
KO mice revealed an increase in the number of centrally located nuclei, swollen 
mitochondria and small atrophic fibers; such changes were accompanied by 
biochemical modifications of the SR with a significant reduction in SERCA1 
expression. Myotubes prepared from wild type, heterozygous and homozygous KO 
mice responded differently to depletion of intracellular Ca
2+
 stores, with myotubes 
from the latter almost completely failing to activate Ca
2+ 
influx. Force measurements 
on muscles isolated from heterozygous KO mice confirm that lack of Stim1 causes 
diminished force development after tetanic contraction and increased susceptibility to 
fatigue [86]. It should be mentioned however, that in mouse muscles STIM1 
expression peaks at embryonic day 8.5-15.5 and muscles from KO mice express low 
levels of MyoD, of MyHC and SERCA. Such a result is compatible with the 
hypothesis that this myopathy may be due to a defect of skeletal muscle development. 
In human myotubes, Stim1-mediated SOCE is required for cell differentiation [87], 
supporting the idea that the severe phenotype of STIM1 KO mice may be due to a 
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maturation or developmental block, whereby muscle cell precursors 
(myoblasts/myotubes) are incapable of developing into mature muscle fibers.  
Patients with Orai1 deficiency have a complex phenotype characterized by 
immunodeficiency, ectodermal dysplasia, a defect of dental enamel calcification and 
subtle histological features suggestive of a congenital myopathy [88]. Interestingly, a 
similar combination of symptoms was observed in a genetically unresolved patient 
with a histopathological diagnosis of MmD, reported before the identification of the 
Orai1 gene [89]. Cells isolated from patients carrying mutations causing reduced 
Orai1expression display impaired Ca
2+
 influx while in zebrafish lack of Orai1 leads to 
loss of skeletal (and cardiac) muscle integrity and myofibrillar disruption [90]. 
Dominant gain of function mutations in STIM1 and ORAI1 are more 
frequently encountered in patients with skeletal muscle involvement. Specifically, 
they have been identified in several patients with childhood or adult onset tubular 
aggregate myopathy [80-82, 91, 92] as well as patients with Stormorken syndrome 
[93,94] a rare disorder characterized by prolonged bleeding, thrombocytopenia/ 
thrombocytopathy, asplenia, intellectual disability, mild hypocalcemia, muscle fatigue 
and tubular aggregate myopathy.  Muscle weakness is generally only mild in the 
adult-onset cases and some of the patients with an ORAI1 mutation presented only 
with exertional cramps [95] Similarly, the phenotype of patients with STIM1 
mutations includes cases with (post-exercise) myalgia, fatigability, and calf 
hypertrophy without muscle weakness [96]. Interestingly, most STIM1 mutations 
identified in patients are located within the NH2 terminal EF hand Ca
2+
 binding 
domain of Stim1, leading to a constitutively active molecule that oligomerizes and 
clusters at ER/PM junctions independently of Ca
2+ 
store depletion. Theoretically, such 
Stim1 molecules should activate Ca
2+
 influx independently of how full the 
intracellular Ca
2+ 
stores are, a hypothesis confirmed in cells carrying STIM1 mutations, 
where it was shown that such cells exhibit dysregulation of Ca
2+ 
homeostasis 
characterized by a high resting [Ca
2+
] and Ca
2+
 entry independent of store depletion 
[82, 91, 92, 94].  
In summary, recent experimental evidence unambiguously supports a role of 
SOCE in normal muscle development. Furthermore, dominant mutations in two 
players of SOCE lead to a myopathy characterized by the accumulation of tubular 
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aggregates deriving from the SR. Nevertheless many questions remain unanswered, in 
particular the mechanism(s) linking STIM1 and ORAI1 mutations to accumulation of 
protein aggregates, how constitutively active Ca
2+ 
influx is not compensated by 
increased activity of Ca
2+
 pumps and extrusion mechanisms and whether alteration of 
Ca
2+ 
influx leads to a chronic activation of the Ca
2+ 
dependent phosphatase calcineurin 
leading to nuclear localization of NFAT.  
2.2.2 Brody’s disease 
Brody’s disease is a rare inherited myopathy due to diminished SERCA1 
activity caused by mutations in ATP2A1 [97]. Since a number of patients do not have 
causative ATP2A1 mutations however, it is now apparent that there is genetic 
heterogeneity in Brody’s disease [98,99]. Consequently it has been proposed to 
distinguish patients with ATP2A1 mutations (“Brody disease”) from patients with 
reduced SERCA1 activity without ATP2A1 mutations (“Brody syndrome”) [100,101] 
Reduced SERCA1 activity results in delayed muscle relaxation due to the prolonged 
increase of the myoplasmic [Ca
2+
] following muscle contraction [102]. Two types of 
SERCA1 are expressed in muscles:  SERCA1 predominantly expressed in type 2 fast-
twitch skeletal muscle and SERCA2 predominantly expressed in type 1 slow-twitch 
and cardiac muscles. Brody’s disease is due to modifications of SERCA1 only, and 
accordingly, no cardiac complications have been reported. Since SERCA1 is only 
present in fast-twitch muscle fibres, impaired relaxation specifically occurs after 
phasic exercises (alternate contraction and relaxation). In contrast, tonic activity (such 
as maintaining posture) requires slow-twitch motor-unit activation, and remains 
unaffected as it predominantly recruits type 1 fibres.  
 Functional studies on muscle samples from humans with Brody’s disease 
have demonstrated that some patients exhibit reduced levels of SERCA1 protein 
content [103,104], while in other cases the levels of SERCA1 protein are unaltered, 
but there is a significant reduction (up to 80%) in the Ca
2+
 pumping activity both in 
homogenates of muscle samples and in myotubes explanted from patients 
[97,104,105]. Chianina cattle pseudomyotonia, a disease similar to Brody’s disease 
affecting cattle is caused by the homozygous ATP2A1 p.R164H mutation [106]. The 
mutation leads to protein instability and therefore reduced SERCA1 expression. 
Pharmacological inhibition of the ubiquitin/proteasomal system rescues the mutated 
SERCA1 protein as well as its enzymatic activity [107]. Such results suggest potential 
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pharmacological treatments for patients with Brody’s disease due to mutations 
leading to decreased protein stability. 
Analysis of the behavior of zebrafish with a naturally occurring mutation in 
acc
dta5
 (the zebrafish homologue of ATP2A1) provides a useful and sensitive model of 
Brody’s disease [108]. Accordion (acc) mutants fail to coil their tails normally after a 
touch-evoked stimulus. In contrast, its trunk muscles contract simultaneously to 
shorten the trunk resulting in a pronounced dorsal bend, which might be considered 
the correlate of a cramp. Subsequent muscle relaxation is significantly slower in acc 
than in wild type zebrafish larvae, corresponding to delayed relaxation in patients. 
Therefore the acc zebrafish mutant is considered a valuable model for the genetic and 
phenotypic evaluation of Brody’s disease and related disorders [108].   
 
2.3 Congenital myopathies due to mutations in genes not directly 
involved in ECC and Ca
2+
 homeostasis 
2.3.1 SEPN1 related disorders 
Selenoproteins are a group of proteins mediating diverse cellular functions 
including the maintenance of the cellular redox status and scavenging reactive oxygen 
species. As their name indicates, members of this family of proteins contain the 
unusual amino acid selenocysteine. Recessive mutations in SEPN1, the gene encoding 
Selenoprotein N (SelN), are commonly associated with a subgroup of MmD and/or 
Rigid Spine Muscular dystrophy (RSMD1), early-onset myopathies with a varying 
but usually severe axial involvement with scoliosis and respiratory failure. In contrast 
to RYR1-related MmD, extraocular involvement is not a typical feature.  To date more 
than 40 SEPN1 mutations have been identified and most if not all of are predicted to 
result in a truncated protein or in diminished levels of SelN expression [109-111]. 
SelN is expressed in the endoplasmic reticulum of all cells, particularly in fetal tissue 
[112], making the mechanistic link between the pathophysiology of SEPN1 mutations 
and neuromuscular disorders difficult to unravel. A first indication connecting SEPN1 
mutations to alterations of Ca
2+ 
homeostasis was provided by Arbogast et al. [113] 
who demonstrated increased stress due to increased reactive oxygen and nitrogen 
species in myotubes from patients with SEPN1-related myopathies. More importantly, 
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Ca
2+
 homeostasis was severely impaired as indicated by: (i) a 30% increase in the 
resting [Ca
2+
], (ii) a 50% reduction in the caffeine-induced peak Ca
2+
 response and 
(iii) a significant depletion of the SR intracellular Ca
2+
 stores. Such an effect was 
putatively attributed to a RyR1 dysfunction due to secondary modification by free 
radicals. These findings are supported by a study by Jurynec et al., who injected 
zebrafish eggs with morpholino oligonucleotides targeted to the exon intron junction 
of the SEPN1 zebrafish homologue [114]. The resulting SEPN1 KO fish display 
reduced swimming activity, sarcomeric disorganization and importantly, decreased 
ryanodine binding capacity and a diminished responsiveness of RyR1 to the 
environmental redox potential, indicating that loss of SelN leads to a deficit of RyR1 
regulation [115]. In order to understand in greater detail the role of SelN in muscle 
physiology, a mouse SEPN1 KO model was created (Sepn1-/-) [116]. Surprisingly, 
under normal housing conditions such mice displayed no overt phenotype, showed no 
alteration of muscle function, their muscles exhibited normal ultrastructural 
organization and there were no changes in the expression levels of RyR1 and Cav1.1 
[117], though they did display a pronounced reduction of the satellite cell population 
[116]. Interestingly, following a bout of challenging physical exercise, Sepn1-/- mice 
showed an obvious phenotype characterized by muscle rigidity and kyphosis 
indicating that in mice muscle use and /or environmental stressful conditions are 
necessary for the myopathy to develop [117].  
Much remains to be investigated concerning the pathophysiological 
mechanism(s) underlying SEPN1-related myopathies and in particular more 
mechanistic insight into its effects on Ca
2+
 homeostasis need to be provided. Studies 
aimed at investigating whether the absence of SelN leads to alterations of RyR1 
function due to changes of its redox status, or secondary posttranslational 
modifications are particularly important as they may reveal mechanisms potentially 
amenable to pharmacological treatment.  
2.3.2 MTM1, BIN1 and DNM2 related disorders 
Mutations in MTM1, the gene encoding the lipid phosphatase myotubularin 1, 
are the underlying cause of X-linked myotubular myopathy (XLMTM), a severe form 
of CNM characterized by generalized muscle weakness, with severe axial, respiratory 
and bulbar muscle involvement [118]. Typically symptoms are already evident at 
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birth and affected males usually die within the first year of life without respiratory 
support. Myotubularin 1 specifically dephosphorylates phosphatidylinositol-3-
phosphate (PI(3)P) and phosphatidinylinositol-3,5-bisphosphate (PI(3,5)P2) to 
produce, PI and PI(5)P, respectively [119]. In humans 14 genes encoding for different 
myotubularin isoforms have been identified and most members of this family play 
important roles in membrane trafficking, movement of intracellular vesicles, 
autophagy and phagocytosis. Though myotubularin 1 is ubiquitously expressed, 
mutations in the MTM1 gene result in a selective skeletal muscle phenotype. Studies 
by Dowling et al. [120], on myotubularin knock down morphant zebrafish suggest 
that the specific muscle involvement is due to the lack of expression in muscle of 
myotubularin related proteins (MTMRs). Such proteins compensate for the lack of 
myotubularin’s enzymatic activity in other tissues. Although a wide range of 
pathogenic mechanisms have been suggested in association with myotubularin 1 
deficiency in the present review we will only focus on mechanisms relevant to Ca
2+
 
homeostasis and ECC.  
Two experimental animal models have greatly advanced our understanding of 
how the absence of myotubularin 1 affects muscle function: the MTM1 KO mouse 
[121] and the MTM morpholino knock down zebrafish [120]. In both animal models 
the most obvious pathological changes occurring in muscle are the presence of 
centrally located nuclei with an abnormal appearance, fiber type 1 hypotrophy, 
abnormal T-tubules and atypical distribution of triads. Muscles from morphant 
zebrafish show reduced ECC with severely impaired muscle contraction evoked by 
stimuli above 10 Hz [120]. Interestingly, tibialis anterior muscles from asymptomatic 
MTM KO mice at three weeks of age show no changes in expression of proteins 
involved in Ca
2+
 homeostasis. However, the tibialis anterior muscles form MTM1 KO 
mice at five weeks of age show a significant decrease in the protein content of RyR1 
and Cav1.1. Concomitantly there is a significant increase in the content of the ß1 
subunit of the DHPR [121]. The latter protein is necessary for proper targeting of the 
1.1 subunit onto T-tubules [122]. Detailed studies on intracellular Ca2+ homeostasis 
showed no difference in the resting [Ca
2+
], nor in the size if the intracellular Ca
2+
 
stores, however the peak [Ca
2+
] evoked by depolarizing pulses was strongly reduced. 
These results support the hypothesis that MTM1 mutations lead to changes in muscle 
function by affecting the expression of the two main Ca
2+ 
channels involved in ECC, 
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but shed no light on the mechanisms linking myotubuarin to the observed changes.  
An interesting hypothesis supported by experimental evidence is that the lipid 
composition of the membranes in which the DHPR and RyR1 are embedded is 
important for their function. Indeed, by confocal immunohistochemistry Dowling et al. 
showed that myotubularin localizes to T-tubules and its distribution overlaps with that 
of the DHPR [120]. Along the same lines, in an elegant report Berthier et al. [123] 
recently demonstrated that PI(4,5)P2, another member of the PI family, is not only a 
constituent of T-tubules, but that its depletion represses electrically evoked Ca
2+
 
release. These results suggest that this lipid may either interact with the RyR1 or 
affect the activity of the voltage sensor. Although PI(4,5)P2 is not a substrate of 
myotubularin 1, alterations in phosphoinositide metabolism due to the accumulation 
of some PIPs may alter the lipid composition of the membrane compartments 
involved in ECC. The absence of myotubularin 1 should theoretically cause an 
accumulation of membrane PI(3)P and PI(3,5)P2 and increased levels of the latter 
lipids negatively affect muscle function by decreasing the size of intracellular Ca
2+
 
stores [124]. While studying the effect of loss of MTMR14 a PI(3,5)P2 lipid 
phosphatase expressed in heart and skeletal muscle Shen et al. [124] showed that (i) 
PI(3)P, PI(5)P and PI(3,5)P2 directly bind to the RyR1 protein; (ii) PI(3,5)P2 activates 
the RyR1 and (iii) PI(3,5)P2 promotes the open conformation of the RyR1 leading to 
Ca
2+
 induced Ca
2+
 release and depletion of Ca
2+
 from SR stores. While Rodríguez et 
al. [125] showed that microinjection of 100 µM PI(3,5)P2 and PI(3) P but not PI(5)P 
significantly elevates the resting [Ca
2+
], while all three phospholipids decrease the 
frequency of spontaneous Ca
2+
 release events in skinned fibers, providing further 
evidence that RyR1 function is sensitive to its phospholipid environment. These 
results are interesting but not altogether compatible with the findings of Al Qusari et 
al. [121] who showed that the skeletal muscles from MTM1 KO mice have normal 
intracellular Ca
2+
 stores and normal resting Ca
2+
 levels and only show a severe 
reduction of electrically evoked Ca
2+
 transients.   
Muscle function has also been extensively studied in a mouse model knocked 
in for MTM1 p.R69C ( c.205C>T) [126], a mutation associated with a less severe 
form of myotubular myopathy [127,128]. The MTM1 p.R69C mutation putatively 
affects the binding domain of PI(3)P/PI(3,5)P2 but not its catalytic domain and should 
therefore result in a phosphatase binding less substrate leading to a hypofunctional 
enzyme. Detailed genetic investigations provided evidence that exon skipping 
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occurred in the mouse model since no full length myotbularin 1 protein was present; 
furthermore the muscle levels of PI(3)P were similar in MTM1 KO mice and mice 
knocked in for the mutation, making the interpretation of the less severe phenotype 
difficult to explain. These observations suggest that aside its lipid phosphatase 
activity, myotubularin 1 may have other functions and may directly regulate the 
activity of proteins involved in ECC thereby contribute to the pathogenesis of 
myotubular myopathy.  
Milder forms of CNM have been associated with dominant and recessive 
mutations in BIN1 and DNM2, encoding the functionally related proteins dynamin 2 
and amphiphysin 2, respectively [129-132]. Dominant mutations in DNM2 are 
associated with defective tubulation [131,132] most likely because they alter the 
function of amphiphysin 2 [131]. Amphiphysin 2 is ubiquitously expressed but the 
skeletal muscle isoform contains a PI binding domain and is localized to the T-tubules 
where it plays an important role in membrane tubulation [133]. Acute down 
regulation of BIN1 by siRNA in mouse FDB fibers recapitulates T-tubule disruption 
as seen in the muscles of affected patients [129]. Furthermore, muscles from BIN1 
knock down mice show profound alterations in Ca
2+
 homeostasis, including depletion 
of intracellular Ca
2+
 stores, reduced membrane current in response to depolarizing 
pulses leading to a reduced Ca
2+
 transient and fewer sparks. Not unexpectedly these 
results confirm that changes in the organization of T-tubules lead to functional 
changes in ECC. Though patients with BIN1 mutations are usually less severely 
affected than patients with MTM1 mutations and may develop a child or adult onset 
congenital muscle diseases [130,134] it should be mentioned that the type of mutation 
plays an important role in the phenotype of the patient and that BIN1 KO mice die 
shortly after birth because of a hypertrophic dilated cardiomyopathy.  
3  Conclusions and outlooks 
The past decade has seen enormous progress in our knowledge concerning the 
pathophysiological mechanisms underlying congenital myopathies; the identification 
of the genetic causes and the functional characterization of mutations in genes 
involved directly or indirectly in Ca
2+
 regulation and ECC have greatly advanced our 
understanding of these diseases. The challenges for the upcoming years will be to 
improve the muscle function and thus the quality of life of affected patients either by 
specifically targeting the genetic defect, as is now being attempted in a preclinical 
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model of MTM1, or by devising pharmacological strategies aimed at targeting 
alternative signaling pathways or pathological loops that are activated in the muscles 
of affected individuals. The increasing availability of different animal models with 
targeted mutations will considerably facilitate the development of experimental 
therapies and identify biomarkers that could be used also to monitor disease 
progression in affected patients. 
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Abbreviations: Cav1.1, alfa 1 subunit of the dihydropyridine receptor; CCD, central 
core disease; CNM, centronuclear myopathy; DHPR, dihydropyridine receptor; ECC, 
excitation contraction coupling; ECCE, excitation coupled calcium entry; ER, 
endoplasmic reticulum; HDAC, histone de-acetylase; MmD, Multi minicore disease; 
MH, malignant hyperthermia; MHS, malignant hyperthermia susceptibility; RyR1, 
ryanodine receptor; SERCA, sarcoplasmic(endoplasmic) reticulum Ca
2+
 ATPase; 
Sele(N), selenoprotein N; SOCE, store operated calcium entry; SR, sarcoplasmic 
reticulum; STIM1, stromal interacting molecule; T-tubules, transverse tubules. 
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FIGURE LEGENDS 
 
Figure 1: Schematic representation of the protein components of skeletal muscle 
sarcoplasmic reticulum (reproduced from [4]). Red spheres represent Ca
2+
 ions; 
yellow spheres represent K
+
 ions. 
 
Figure 2: Prolonged depolarization induces nuclear translocation of NFAT and 
may be linked to increased level of circulating IL-6. A. Myotubes from a control 
and CCD individual were untreated or treated with 500 µM ryanodine and incubated 
with 60 mM KCl for 20 seconds and then with Krebs Ringer for a total of 5 minutes 
at 37°C. Cells were fixed and processed for immunofluorescence. Images (60X TIRF 
objective) show epifluorescence using anti-NFATc1 Ab (green) and DAPI (blue) for 
nuclear staining. Bar =30 µm. B. Bar histograms showing the nuclear to cytoplasmic 
NFATc1 fluorescence intensity in cells from 3 different control individuals (n ranged 
between 25-35 individual cells) and 2 different CCD individuals (n ranged between 
32-38 individual cells) in untreated cells (white bars) and cells treated with 60 mM 
KCl plus 2 mM Ca
2+
 for 20 seconds and then incubated with Krebs Ringer for 5 min 
(light grey) or 30 min (dark grey). The area over the nucleus was selected using the 
DAPI image and transferred to the NFATc1 fluorescence image using the “transfer 
region option” of the Metamorph software package. Average fluorescent intensity in 
nuclei and region excluding nuclei were calculated with Metamorph. *P<0.03 
compared to controls (from [53]). C. Plot of (logarithmic) serum concentrations of IL-
6 in different groups of patients. Each symbol represents the mean triplicate IL-6 
value obtained from a single individual. P values were statistically significant 
between controls and MHS individuals and control and CCD patients. 
Figure 3 Cartoon depicting how mutations in RYR1 may lead to a decrease in 
RyR1 content. Recessive mutations in the RYR1 gene are accompanied by epigenetic 
modifications leading to DNA hyper-methylation and HDAC-4/HDAC-5 over-
expression. This causes mef-2 sequestration thereby inhibiting transcription of genes 
regulated by mef-2, including the RYR1 and muscle-specific miRs. A decrease in 
RyR1 would severely affect muscle excitation-contraction coupling since this calcium 
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channel is a central player in this mechanism, releasing the calcium necessary for 
muscle contraction from the sarcoplasmic reticulum. 
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